Business
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
HAMPTON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s barzolvolimab program
About this update from Celldex Therapeutics, Inc.
[{"type":"text","content":"HAMPTON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s barzolvolimab program will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2023 being held June 9-11 in Hamburg, Germany. PRESENTATION DETAILS Late Breaking Oral Presentation Number 000401: Barzolvolimab Demonstrates Clinical Activity in a Multiple Ascending Dose Trial in Chronic Spontaneous UrticariaSession Date & Time: Saturday, June 10, 2023, 12:00 - 1:00 pm CEST; 6:00 - 7:00 am EDTSession: Urticaria and angioedema from bench to bedsidePresenting Author: Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité - Universitätsmedizin in Berlin Oral Presentation Number 000393: Barzolvolimab Demonstrates Clinical Activity in Antihistamine Refractory Cholinergic UrticariaSession Date & Time: Saturday, June 10, 2023, 4:45 pm - 6:15 pm CEST; 10:45 am - 12:15 pm EDTSession: Novel treatment approaches in urticariaPresenting Author: Eva Grekowitz, M.D., Clinical Investigator, Department of Dermatology, Venerology and Allergy at Charité - Universitätsmedizin in Berlin About Celldex Therapeutics, Inc.Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com. Forward Looking StatementThis release contains \"forward-looking statements\" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as \"believes,\" \"expects,\" \"anticipates,\" \"intends,\" \"will,\" \"may,\" \"should,\" or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should...